Lv1
30 积分 2025-10-23 加入
Anlotinib plus TQB2450, a PD-L1 Antibody, in Patients with Advanced Alveolar Soft Part Sarcoma: A Single-Arm, Phase II Trial
25天前
已完结
Anlotinib plus TQB2450, a PD-L1 Antibody, in Patients with Advanced Alveolar Soft Part Sarcoma: A Single-Arm, Phase II Trial
25天前
已完结
Anlotinib in progressive RAI-refractory differentiated thyroid cancer: long-term results and PET/CT prognostic markers
2个月前
已关闭
Anlotinib in progressive RAI-refractory differentiated thyroid cancer: long-term results and PET/CT prognostic markers
2个月前
已完结
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
3个月前
已完结
Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup
3个月前
已完结
Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas
3个月前
已完结
Multicenter randomized double-blind phase ll trial of donafenib in progressiveradioactive iodine-refractory differentiated thyroid cancer
3个月前
已完结
Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma
5个月前
已完结
Histologic and Immunologic Factors Associated with Response to Immune Checkpoint Inhibitors in Advanced Sarcoma
6个月前
已完结
皖公网安备34019202002308
